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Dose-dependent effects of strontium on osteoblast function
and mineralization.
Background. Strontium-ranelate is now being used in the
treatment of osteoporosis in elderly patients. As the majority
of these patients already have a decreased renal function they
are at an increased risk for accumulation of the element. Recent
findings from epidemiologic studies in dialysis patients and
experimental data obtained in a chronic renal failure (CRF)
rat model established a dose-related multiphasic effect of stron-
tium (Sr) on bone formation. To confirm these in vivo findings
an in vitro set-up, consisting of primary rat osteoblast cultures,
was applied. Sr was added to the culture medium at concentra-
tions of 0, 0.5, 1.0, 2.0, 5.0, 20, and 100 g/mL, respectively.
Methods. Calcium incorporation (index of mineralization)
and alkaline phosphatase activity were determined in the me-
dium during the culture period, while at the end of the experi-
ment, nodule formation (mineralized  unmineralized area)
was quantified using a digital imaging system. mRNA synthesis
of various osteoblast specific genes was assessed by means of
reverse transcription polymerase chain reaction (RT-PCR).
Results. Compared to the control group (0 g/mL Sr), a
significantly reduced nodule formation in the presence of an
intact mineralization was found for the lowest 0.5 and 1 g/mL
Sr doses, suggesting an impaired in vitro osteoblast differentia-
tion. Both nodule formation and mineralization were normal
for the 2 and 5 g/mL doses. For the highest Sr doses (20
and 100 g/mL) a reduced mineralization was observed in the
presence of an intact nodule formation indicating an inhibitory
effect on the hydroxyapatite formation. The alkaline phospha-
tase activity reflected the multiphasic pattern of the nodule
formation while the calcium incorporation corresponded with
the pattern of nodular mineralization. No variations in cell
proliferation were found. RT-PCR revealed that Sr interfered
with the osteoblast at the level of the mRNA synthesis of
several relevant genes.
Conclusion. Using the proposed in vitro model we con-
firmed the multiphasic effect of Sr on bone formation pre-
viously demonstrated in a CRF rat model. The data presented
allow us to suggest that at low concentrations Sr interferes
with the bone formation at the level of cell differentiation,
whereas at high concentrations the disturbed mineralization in
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the presence of an intact nodule formation is indicative for a
physicochemical interference of Sr with the hydroxyapatite
formation.
Due to its chemical analogy to calcium (Ca), strontium
(Sr, molecular weight 87.62) is a bone-seeking element
that readily exchanges for Ca in diverse tissues, including
the hydroxyapatite lattice in bone [1, 2]. Evidence has
been presented that in subjects with normal renal func-
tion, a high Sr diet goes along with an increased amount
of the element in the bone mineral [3]. Because the kidney
is the main excretion route of Sr (clearance 4.0 to 5.4
mL/min) [4] and dialysis fluids may be contaminated with
the element, dialysis patients are at an increased risk for
accumulation/toxic effects of the element [5–7].
Data from previous studies of our group showed that:
(1) bone Sr concentrations are increased in dialysis pa-
tients with osteomalacia—a type of renal osteodystrophy
characterized by a defective mineralization in the presence
of large osteoid seams—as compared to those presenting
the other types of renal osteodystrophy [5, 6]; (2) osteo-
malacia can be induced in a chronic renal failure (CRF)
rat model after oral administration of the element (0.3%
in the drinking water during 12 weeks) [8], indicating
that Sr may play a causative role in the development of
this particular type of renal osteodystrophy; and (3) Sr
exhibits a multiphasic and dose-dependent effect on bone
formation/mineralization in CRF rats. Indeed, whereas a
low Sr dose (0.03% in the drinking water during an 18-
week loading period) leads to the development of an
adynamic bone, normal bone histology was noted with
the intermediate dose (0.075%), while administration of
a high Sr dose (0.150%) again resulted in the develop-
ment of severe osteomalacic lesions [9]. A dose-depen-
dent effect of Sr on bone has previously been reported
by Marie et al [10] in rats with normal renal function
also. Here, at low doses (0.19%) a stimulation of bone
formation was observed, whereas at higher doses (0.40%)
a defective mineralization was noticed. Similar ambigu-
ous effects have also been demonstrated for aluminum,
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which, dependent on the degree of exposure, are ex-
pressed by either the development of adynamic bone or
osteomalacia [11–13].
The clinical relevance of the present investigations
needs to be emphasized since Sr is now being used as
the Sr-ranelate compound for the treatment of osteopo-
rosis in elderly patients in doses up to 2 to 3 g/day [14].
As the majority of these patients already have a de-
creased renal function (60 mL/min), they are at an
increased risk for accumulation of the element. Although
the effects of Sr on bone have substantially been investi-
gated in vivo [2, 6–10], until now, no long-term in vitro
cell culture experiments have been performed, which
contributes to the fact that [10, 15] the mechanisms un-
derlying the element’s ambiguous effects on bone are
poorly understood. To investigate whether the multipha-
sic effects of Sr observed in vivo can be reproduced and
confirmed under standardized in vitro conditions, the
present study, using a cell culture model consisting of
primary osteoblasts isolated from 20-day-old fetal rat
calvaria, was set up. The influence of various concentra-
tions of stable Sr on a series of relevant physicochemical
and biochemical parameters involved in the bone forma-
tion/mineralization process was examined under well-
controlled conditions, aiming to investigate whether the
effects of Sr on bone formation either are osteoblast-
mediated and/or result from a direct physicochemical
effect of the element on the hydroxyapatite formation.
METHODS
Experimental design
Primary osteoblasts were isolated from fetal Wistar
rat calvaria. Calvaria were dissected aseptically from 20-
day-old fetuses of timed-pregnant Wistar rats. After dis-
section, loosely adherent soft connective tissue was re-
moved and calvaria were minced into1 mm3 fragments
which were placed on an 80  nylon mesh, pressed be-
tween two rings in -minimal essential medium (MEM)
medium (Life Technologies, Merelbeke, Belgium) sup-
plemented with 10% fetal bovine serum (FBS) and 50
g/mL ascorbic acid. After 2 or 3 days a significant cellu-
lar outgrowth from the calvaria fragments was observed.
Medium was then refreshed every 2 days during 7 to 9
days until the cultures reached confluence. Nylon meshes
containing the confluent cultures were subsequently cut
from the rings and trypsinized to harvest the outgrown
cells. These cells were seeded in 6-well plates at a density
of 6000 cells/cm2 in -MEM medium enriched with
ascorbic acid (100 g/mL) until confluence was reached.
After confluence both ascorbic acid (100 g/mL) and
-glycerol phosphate (2 mmol) were added to obtain cul-
ture conditions ensuring a reproducible mineralizing cul-
ture. To minimize dedifferentiation of the primary osteo-
blasts, no further passages were used in these experiments.
Sr was added to the medium of the confluent cultures
at various amounts as the chloride compound SrCl2.6H2O
(Merck, Leuven, Belgium), yielding final Sr concentra-
tions of 0.5, 1.0, 2.0, 5.0, 20, and 100 g/mL. Cells were
kept in culture for three weeks. The choice of the concen-
trations was based on the results of an in vitro pilot study
and on the serum Sr levels at which a dose-dependent
effect of the element on bone was demonstrated in a
CRF rat model [8, 9]. As control, we used medium to
which: (1) no Sr; (2) 104 mol levamisole; and (3) 60
mol pyrophosphate (Na4P2O7H2O) (Acros, Geel, Bel-
gium) were added. Here, levamisole acts as an inhibitor
of alkaline phosphatase, while pyrophosphate is a well-
known crystal poison of apatite crystal formation/growth
[16–19]. Hence, these compounds served as internal con-
trols for the in vitro osteoid (i.e., nodule) deposition and
bone mineralization. Three independent parallel experi-
ments were set up to check the reproducibility of the
effects of Sr on the in vitro bone formation. During
the course of the experiment the culture medium was
refreshed 3 times per week during the three-week period.
Before each refreshment medium samples were taken
and frozen at –80C until measurement of the various
parameters under study (see below).
Hydroxyapatite analysis
Mineralized cultures (to which no Sr was added) were
fixed in 90% ethanol, air-dried, and analyzed with a
JEOL JSM 6300 scanning electron microscope (JEOL
Europe, Zawentem, Belgium) for morphologic examina-
tions. Using the same apparatus, the elemental composi-
tion of the deposited mineral was determined by means
of Electron Probe X-ray Micro Analysis (EPXMA) (JEOL
Europe).
In addition to this technique, unfixed mineralized cul-
tures were air dried for Fourier Transform Infra Red
(FTIR) analysis to further identify and characterize the
deposited mineral. After mixing the samples with potas-
sium bromide, FTIR spectra were recorded on a Nicolet
20 DXB FTIR-spectrometer (Nicolet Instrument Corpo-
ration, Madison, WI, USA). Three hundred scans were
taken in the mid infrared (IR)-range (400 to 4000 cm1).
Sr determination
Measurement of Sr in the culture medium was done
using a Zeeman 3030 atomic absorption spectrometer
equipped with an HGA-600 graphite furnace (Perkin
Elmer Corporation, Ueberlingen, Germany), as pre-
viously described in detail [20]. With this method atom-
ization was performed from the wall of pyrolytically coated
graphite tubes. Calibration was performed against matrix-
matched calibration curves. The medium samples were
diluted in a 0.5 mL/L Triton X-100  1 mL/L HNO3
solution.
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Fig. 1. (A ) Light microscopic photograph of
a partially mineralized nodule of a control pri-
mary osteoblast culture. Upper panel, Grey
lines enclose the total nodule area while white
lines contain the mineralized area of the total
nodule as measured by the digital image analy-
sis. Subtracting the mineralized area from the
total nodule area yields the unmineralized
area (magnification, 	100). EPXMA spec-
trum of a mineralized nodule and (lower panel)
matching scanning electron microscopic im-
age (bar represents 10 ). The 10/6 Ca/P ratio
(middle panel) confirms the deposited mineral
to be Ca hydroxyapatite. (B ) Upper panel,
FTIR spectra of pure Ca hydroxyapatite; mid-
dle panel, pulverized animal bone; lower panel,
mineralized primary rat osteoblast culture.
Peaks at 1030, 605, and 560 cm1 are character-
istic for Ca hydroxyapatite. EPXMA is elec-
tron probe x-ray micro analysis; FTIR is Fou-
rier transform infra red.
Ca incorporation
Medium samples were taken before and after each
incubation period to measure the Ca concentration. The
decline in the Ca concentration in the medium after
incubation was used as a measure of Ca incorporation
into the mineralized nodules (i.e., hydroxyapatite forma-
tion). After integration over the different time points
the Ca incorporation was expressed as the absolute
amount of incorporated Ca (g) over time [area under
the time-concentration curve (AUC) of 11 time points].
This method was used as an alternative for the previously
described radioactive 45Ca-incorporation method [18, 21].
Ca was determined by means of flame atomic absorption
spectrometry using a Perkin Elmer 372 (Perkin Elmer
Corporation) instrument by a modification of the tech-
nique of Hansen [22]. To overcome the problem of chem-
ical interference due to the presence of phosphate and
high salt content of the samples, 1/50 dilutions of the
samples were made in 0.1% La(NO3)3.
At the end of the experiment, for each of the cultures
the total amount of incorporated Ca was compared to
the area of the mineralized sections of the nodules mea-
sured by quantitative microscopic digital image analysis
(KS-400; Kontron Embedded Computer AG, Munchen,
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Germany). Within the nodules, differentiation between
mineralized and unmineralized nodule area was done
based on the difference in gray value following a modi-
fied protocol from Nefussi et al [23] (Fig. 1A, upper panel).
Phosphorous measurement
Total phosphorous content was measured in the cell
culture medium before and after incubation on a Vitros
950 AT Autoanalyzer System (Ortho Clinical Diagnos-
tics, Johnson & Johnson, Raritan, NJ, USA).
Alkaline phosphatase assay
Alkaline phosphatase activity in the conditioned cul-
ture medium was determined spectrophotometrically by
measurement of the release of p-nitro phenol from p-nitro
phenolphosphate. The enzyme activity was determined
as the change in absorbance at 405 nm over a 10 minutes
period. This procedure is based on the kinetic method
for measuring total alkaline phosphatase acknowledged
by the International Federation of Clinical Chemistry
(IFCC) [24].
Electrophoresis of alkaline phosphatase
To check whether Sr has a direct effect on the enzy-
matic activity or electrophoretic mobility, a serum sam-
ple with a known bone alkaline phosphatase activity was
incubated with various Sr concentrations, after which
the isoenzymes were separated by agarose gel electro-
phoresis according to the method described by Van Hoof
et al [25]. Neuraminidase was used to separate liver and
bone alkaline phosphatase during electrophoresis. After-
wards, the enzymatic activity was quantified by densitom-
etry at 640 nm after incubation with 2-bromo-4-chloro-
3-indoxyl phosphate at pH 10.6.
DNA assay
Using the Fluoreporter Blue Fluorometric dsDNA
quantitation kit (Molecular Probes, Leiden, The Nether-
lands), the concentration of double-stranded DNA
(dsDNA) was determined in cultures of the various study
groups to check for possible Sr-mediated differences in
cell number. DNA measurements were performed at
one time point before confluence and at three different
time points after confluence.
5-bromo-2-deoxyuridine (BrdU) incorporation
The effects of Sr on the proliferation of primary osteo-
blasts were determined using a cell proliferation enzyme-
linked immunosorbent assay (ELISA) BrdU kit (Roche,
Basel, Switzerland). At two different time points precon-
fluence, as well as at five time points postconfluence,
cells cultured in 48-well plates and exposed to different
Sr concentrations were incubated with BrdU labeling
solution for 24 hours at 37C. Following the manufactur-
er’s instructions, cells were fixed for 30 minutes and
incubated with the anti-BrdU antibody for 90 minutes.
After several washing steps and addition of the substrate,
the color intensity was measured spectrophotometrically
at 450 nm.
Reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from primary osteoblasts
exposed to the different Sr concentrations 18 days’ post-
confluence using the standard protocol from the High
Pure RNA Isolation Kit (Roche), including a DNase I
treatment to eliminate possible DNA contamination.
The total RNA concentration in the isolates was quanti-
fied by spectrophotometry at 260 nm. One g of the
RNA extract was used to precheck the RNA quality by
electrophoresis on a 2% agarose gel, after which aliquots
of the RNA isolate were frozen at 80C until analysis.
Reverse transcription-polymerase chain reaction (RT-
PCR) was performed for the following genes: alkaline
phosphatase (ALP); bone sialoprotein (BSP); osteopon-
tin (OPN); bone morphogenic protein-2 (BMP-2); core
binding factor alpha 1 (CBFa-1); and glyceralgdehyde-
phosphate dehydrogenase (GAPDH), which was applied
as housekeeping gene. PCR primer sequences and frag-
ment length for the different genes under study are,
respectively: ALP F: 5
-GCTACACCACAACACGG
GCGA-3
, R: 5
-TCCAAATGCTGATGAGGTCCA-3
,
550 bp; BSP F: 5
-AAGAAGGCTGGAGATGCAGA
GGG-3
, R: 5
-GAGGTGGTCCCATAGGCTTCG-3
,
350 bp; OPN F: 5
-TGAGACTTGCAGTGATTTGCTT
TTGC-3
, R: 5
-CTCATCTGTGGCATGGGGATAC
TG-3
, 519 bp; BMP-2 F: 5
-GCTGTCTTCTAGTGTTG
CTGCTT-3
, R: 5
-TTCGGTGCTGGAAACTACTAT-3
,
485 bp; CBFa-1 F: 5
-CTTCATTCGCCTCACAAACA
ACC-3
, R: 5
-AAGAAGTTTTGCTGACACGGT-3
,
286 bp; GAPDH F: 5
-ACCACAGTCCATGCCATC
AC-3
, R: 5
-CCACCACCCTGTTGCTGTA-3
, 450 bp.
Using the Superscript One Step RT-PCR kit (Invitrogen,
Merelbeke, Belgium), reverse transcription was performed
at 50C for 30 minutes for all samples following the
standard procedures supplied by the manufacturer. After
amplification in a Gene Amp 9600 PCR System (Perkin
Elmer), a 10 L quantity of each PCR product was
then electrophoresed on a 2% agarose gel (E-gel system;
Invitrogen), visualized, and quantified on a Lumi Imager
(Boehringer Mannheim).
Statistics
Data are expressed as mean  SD unless otherwise
stated. For each of the various study parameters, compar-
ison of the various study groups (i.e., different Sr concen-
trations) versus the control group (0g/mL Sr) was done
by ANOVA. In case more than two groups were com-
pared, a post-hoc Bonferroni test was applied to correct
for the number of comparisons. Statistical significance
was obtained when P  0.05 at a two-tailed level.
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Fig. 2. (A ) Nodule area expressed as mm2/
cm2 quantified at the end of the experiment.
Black bars represent the mineralized area and
open bars represent the unmineralized area
of the nodules. For the quantitative represen-
tation of the degree of mineralization calcu-
lated as the percentage of mineralized nodule
area see Results. *P  0.05 vs. control. (B )
Unstained cultures showing the mineralized
nodules of the corresponding cultures at the
end of the incubation period (magnification,
	1). (C ) Area under the time-Ca incorpora-
tion curve. Data are expressed as g Ca incor-
porated per well (corrected for DNA content)
and presented as the mean  SD calculated
from 6-pooled wells of 3 different cultures.
*P  0.05 vs. control. (D ) Area under the
time-concentration curves for alkaline phos-
phatase expressed in U/L calculated from 6-
pooled wells of 3 different cultures, each of
them measured in duplicate and corrected for
DNA content. Data are presented as mean 
SD. *P  0.05 vs. control.
RESULTS
Mineralization
Cells seeded at 6000 cells/cm2 in 6-well culture plates
reached confluence within 7 days. Nodule formation was
observed from day 7 post-confluence. As assessed in con-
trol cultures these nodules were mineralized within 15
days after confluence (Fig. 1A, upper panel). EPXMA
spectra of the mineralized nodules revealed a Ca/P ratio
of 10/6, which reflects the stoechiometric composition of
the bone mineral [Ca10(PO4)6(OH)2] in the in vivo situation
(Fig. 1A, middle panel). Moreover, comparison of the
FTIR spectra of the in vitro deposited mineral with those
of synthetic Ca hydroxyapatite and pulverized animal
bone revealed the typical absorbance peaks of hydroxy-
apatite at 1030, 600, and 560 cm1 (Fig. 1B, upper panel,
and lower panel), confirming the EPXMA data. These
results thus present evidence that the in vitro formed
mineral is hydroxyapatite, the main compound of bone.
Effect of Sr on expression of the
phenotypic characteristics
Determination of the Sr content in the culture medium
revealed values accurately reflecting the values noted for
the Sr additions of 0, 0.5, 1, 2, 5, 20, and 100 g/mL Sr2.
Verbeckmoes, De Broe, and D’Haese: Strontium and in vitro mineralization 539
Nodule formation. Quantitative microscopic analysis
of the nodule formation by measuring the nodule area
in the culture showed an Sr-related multiphasic pattern
(Fig. 2A). In the control group, a total nodule area
(mineralized  unmineralized sections) of 31.5  10.3
mm2/cm2 was found, 76.8 10.3% of which was mineral-
ized (N  10). Compared to the control group, total
nodule area was significantly (P  0.05) decreased in
the groups treated with 0.5 and 1 g/mL Sr (11.2  7.8,
13.9 12.2 vs. 31.5 10.3 mm2/cm2; N 10 in all groups),
whereas no difference was found for the 2, 5, 20, and
100 g/mL treatment groups (25.0  7.0, 29.8  7.0,
28.9  8.8, 24.8  7.9 vs. 31.5  10.3 mm2/cm2; N  10
in all groups). The mean size of the nodules was not
different between the different groups (data not shown).
Differentiation between the mineralized and unmineral-
ized nodule areas allowed us to calculate the degree of
mineralization as the percentage of the total nodule area
covered by hydroxyapatite deposits (mineralized area/
total area 	 100) (Fig. 2B). By doing so, in the 0.5 and
1 g/mL Sr groups the mineralization appeared to be
intact despite the decreased nodule formation (64.4 
34.4, 46.4 41.4% vs. 76.8 10.3% in the control group;
NS; N  10 in all groups). The intermediate groups (2.0
and 5.0 g/mL Sr) did not differ from the control group,
as the normal nodule formation was accompanied by an
intact mineralization (79.9 8.7 and 75.0 10.1 vs. 76.8
10.3%; NS; N  10 in all groups) However, in the 20
and 100 g/mL treatment groups, the mineralization was
significantly impaired in the presence of an intact nodule
formation (14.7  20.4, 9.1  15.0 vs. 76.8  10.3%; P 
0.05; N  10 in all groups).
For the levamisole group (alkaline phosphatase inhibi-
tor) both the total nodule area (9.6  3.5 mm2/cm2; N 
10) and the ratio of the mineralized area/total nodule
area (4.2  13.2%) were significantly (P  0.05) lower
than the control group (31.5  10.3 mm2/cm2 and 76.8 
10.3%, respectively; N  10). The pyrophosphate group
revealed a pattern comparable to that noted for the 20
and 100 g/mL Sr groups (i.e., a decreased mineralized
area versus the control group in the presence of an un-
changed total nodule area (ratio, 47.5 15.3% vs. 76.8
10.3%; P  0.05; N  10).
Ca incorporation. The Ca incorporation showed an
Sr-dependent multiphasic pattern similar to the calcu-
lated mineralized nodule areas determined by quantita-
tive microscopic imaging (Fig. 2C). Indeed, in the 0.5, 1,
20, and 100 g/mL Sr groups, the amounts of incorpo-
rated Ca were significantly lower than the values mea-
sured for the control group (221.8  28.3, 189.4  23.6,
222.4 49.1, 124.2 10.3 vs. 323.6 13.1g Ca incorpo-
rated; P  0.05; N  18 in all groups), while the 2 and
5 g/mL Sr groups did not differ significantly (252.3 
62.4 and 285.1 25.6 vs. 323.6 13.1g Ca incorporated;
N  18 in all groups). In both the pyrophosphate, and
Fig. 3. BrdU-incorporation in the different groups under study in func-
tion of time. No significant differences between the different groups
were found.
even to a higher extent in the levamisole group, the Ca
incorporation was significantly decreased versus the 0
g/mL control group (211.8  53.1, 147.4  38.3 vs.
323.6  13.1 g Ca incorporated; P  0.05; N  18),
which again was in agreement with the data obtained by
digital image analysis.
Measurement of the total phosphorous concentration
before and after incubation revealed no significant differ-
ences between the different treatment groups, which was
due to the high background phosphorous level resulting
from the large excess present in the culture medium.
Alkaline phosphatase. The addition of Sr to the cul-
ture medium affected the alkaline phosphatase activity
in a multiphasic way, similar to that seen for the quantifi-
cation of the total nodule formation. Enzymatic activity
was significantly (P  0.05) decreased in the 0.5, 1, and
2 g/mL groups versus the control group (49.7  6.3,
79.7 1.2, 88.7 10.0 vs. 121.1 15.5 U/L, respectively;
N  18 in all groups). The inhibitory effect in these
groups was comparable to that noted for the levamisole
group (enzymatic activity, 50.8  0.7 U/L; N  18). No
significant difference was found in the 5, 20, and 100
g/mL groups versus control. Alkaline phosphatase ac-
tivity was significantly (P  0.05) increased in the pyro-
phosphate group (168.2  15.1 U/L; N  18) versus all
other groups.
To examine whether the observed multiphasic effect
of Sr on alkaline phosphatase was due to an interference
of the element with the cellular secretion/synthesis of
the enzyme rather than being the result of a direct inter-
action with the enzyme activity, the electrophoretic mo-
bility and enzymatic activity of a serum sample incubated
with the different Sr-concentrations was also assessed.
No difference in the electrophoretic pattern or in signal
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Fig. 4. RT-PCR analysis demonstrating the
mRNA expression of ALP, BMP-2, BSP, CBFa-1,
and OPN. RT-PCR was performed in duplo
on mRNA isolates from three independent
cultures (N  6) treated with various doses of
Sr. Quantitative data of the expression levels
of the different genes are expressed as mean
SEM and corrected for the mRNA expression
of GAPDH. Abbreviations are: RT-PCR, re-
verse transcription-polymerase chain reaction;
ALP, alkaline phosphatase; BMP-2, bone
morphogenic protein-2; BSP, bone sialopro-
tein; CBFa-1, core binding factor alpha 1;
OPN, osteopontin; GAPDH, glyceraldehydes-
3-phosphate-dehydrogenase.
intensity could be observed between the various groups.
The absence of any difference in enzymatic activity was
further confirmed using the standard procedure with
p-nitro phenolphosphate as substrate (data not shown).
Multiphasic effects of Sr on both Ca incorporation
and alkaline phosphatase were consistent in function of
time for all the groups under study and no time-depen-
dent difference or time shift was observed (Fig. 2D).
Total DNA content and cellular proliferation. To ex-
amine whether the observed Sr-induced effects on the
different parameters were due to an interference of the
element with the cellular proliferation, total DNA con-
tent and BrdU-incorporation of the different groups un-
der study were determined at different time points pre-
and postconfluence. No difference in the DNA content
or in the BrdU-incorporation (Fig. 3) between the groups
could be observed.
RT-PCR analysis. Reverse transcription-polymerase
chain reaction analysis on cell lysates of the different groups
at sacrifice of the culture (i.e., 18 days’ post-confluence)
also revealed a multiphasic effect of Sr on the mRNA
expression of alkaline phosphatase and bone sialoprotein,
the effect being pronounced most intensively in the 0.5
g/mL group, as shown in Figure 4. A multiphasic effect
was also seen for the osteoblast-specific transcription
factor CBFa-1 and BMP-2, which were particularly de-
creased in the 1 g/mL group. No such effect was found
on the mRNA expression of osteopontin. RT-PCR anal-
ysis was performed in duplo on samples taken from 3
independent cultures (i.e., 6 measurements for each gene).
DISCUSSION
In previous studies, increased bone Sr levels were noted
in dialysis patients with osteomalacia [5, 6]. A causative
role for Sr in the development of osteomalacia was dem-
onstrated by our group in a rat model with chronic renal
insufficiency [8]. In addition, in these experimental stud-
ies the effect of Sr on the bone formation/mineralization
was found to be dose dependent [9]. Here, at low doses
an adynamic, and at high doses an osteomalacic bone
lesion could be induced. In rats with normal renal func-
tion Marie et al [10] found also a dose-dependent effect
of Sr on the bone metabolism. The mechanisms underly-
ing these effects are poorly understood. The present in vitro
model consisting of mineralizing osteoblasts was used to
investigate whether (1) it was possible to reproduce the
causal, dose-dependent effects of Sr as previously ob-
served in vivo; (2) the effects of Sr on bone mineraliza-
tion are osteoblast-mediated; and (3) and/or result from
a direct physicochemical effect.
Primary rat osteoblast cultures isolated from 20-day-
old fetal rat calvaria were used. This model has previously
been applied by others studying the in vitro osteogenesis
[26–30], and to investigate the effects of trace elements
other than Sr on the in vitro mineralization [31–35]. With
the in vitro set-up of the present study, the temporal
evolution of the major phenotypic characteristics (alka-
line phosphatase and Ca incorporation) involved in the
mineralization process (data not shown) agrees with pre-
vious literature data [28] and is assumed to represent
well the in vivo situation. Moreover, EPXMA analysis
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of the mineralized nodules revealed a Ca/P ratio of 10/6,
which corresponds with the ratio found in the hydroxyap-
atite lattice [Ca10(PO4)6(OH)2] of animals and humans.
These results were further confirmed by FTIR yielding
spectra of the deposited mineral similar to those of syn-
thetic apatite and pulverized animal bone.
Quantification of nodule formation was primarily
done by measuring the nodule area. Following a modified
protocol from Nefussi et al [23], by using a microscopic
digital imaging system it was possible to distinguish be-
tween the mineralized and unmineralized portions of the
nodules without the need for staining since the deposited
mineral in the nodules can be observed as highly con-
trasting dark areas, while the unmineralized portions can
be easily differentiated from the background (Fig. 1).
Aside from nodule counting, this method has the advan-
tage of providing quantitative information about the de-
gree of mineralization of the nodules. Since the mean size
of the nodules was not different between the different
groups, the quantification of the total nodule area also
reflects the number of the nodules. Additional to this
microscopic method, quantification of the degree of min-
eralization was assessed by measuring the daily decrease
of the Ca concentration in the conditioned medium. This
decrease was calculated by comparing the total Ca con-
tent in the medium before and after cellular incubation
with each refreshment of the medium. By doing so, mea-
surement of the Ca incorporation offers the possibility
to easily quantify the in vitro mineralization in one and
the same culture at various time points without the need
to sacrifice the cultures or to use radioactive isotopes
[18]. Results obtained by this method also indicated a
multiphasic effect of Sr on the mineralization process.
It should be mentioned that at the highest concentrations
the variation in the Ca incorporation does not seem to
match very well with the variation in the mineralized
nodule areas seen by image analysis. This might be ex-
plained by our preliminary results of the x-ray diffraction
analysis of the in vitro deposited hydroxyapatite, per-
formed at the European Synchrotron Radiation Facility
(ESRF, Grenoble, France, beamline ID18F), revealing
that high Sr concentrations give rise to diffusely depos-
ited amorphous mineral reflecting a defective mineraliza-
tion [abstract; Verberckmoes SC et al, J Am Soc Nephrol
12:577A, 2002]. This type of defective mineralization
cannot be quantified by visual examination in unstained
cultures (image analysis), but goes along with a sustained
Ca consumption that will be detected by measuring the
Ca incorporation. Moreover, whereas the microscopic
quantification of the mineralized area only gives two-
dimensional information (nodule area), the Ca incorpo-
ration provides three-dimensional information (nodule
volume) of the Ca consumption during the total mineral-
ization process.
Using this validated model of in vitro bone formation
we could confirm the multiphasic effects previously ob-
served in vivo and present evidence for Sr to exert a cell
biological effect at low doses, and a physicochemical
effect on bone formation/mineralization at high doses.
The reduced nodule formation at the lowest Sr concen-
trations (0.5 to 1 g/mL) was not accompanied by an
impaired mineralization, since in these groups the ratio
of the mineralized area/total nodule area did not differ
from those of the control group. It is generally assumed
that nodule formation goes along with the differentiation
of osteoprogenitor cells toward mature osteoblasts [26,
28, 32, 36]. Since in the present study Sr was added to
the culture from the moment of confluence onward, and
because there was not any difference in DNA content
and BrdU incorporation between the different groups,
the observed differences in total nodule formation (min-
eralized  unmineralized) between the different doses
could not be due to a change in proliferation. Hence, as
previously proposed by others in the context of different
experimental set-ups [26–28, 31, 32, 37], the altered nod-
ule formation most reasonably must be due to alterations
in osteoblastic differentiation.
The electrophoretic data of alkaline phosphatase indi-
cate that the observed effect of Sr on the activity of the
enzyme in the culture medium was not due to a direct
interaction of Sr with the intact metalloenzyme, but rather
occurs secondary to a cellular response. This suggestion
is further supported by the results obtained by RT-PCR
analysis. Here, the mRNA expression of alkaline phos-
phatase was also affected in a multiphasic way similar
to the pattern for its enzymatic activity. This multiphasic
pattern, and more particularly, the inhibition of the ex-
pression at low Sr concentrations, was also observed on
other osteoblast-specific factors, such as bone sialopro-
tein, BMP-2, and CBFa-1 [26, 28]. Data from the litera-
ture clearly show that BMP-2 and CBFa-1 are closely
involved in the osteoblast differentiation process [38–
42]. Hence, the RT-PCR data, together with the effects
on the nodule formation, support the suggestion that the
observed effects of Sr at low doses are mediated by an
inhibitory effect on osteoblast differentiation. No clear
significant effect could be demonstrated for osteopontin,
which most probably was due to its very low expression
and, hence, relatively low signal/noise ratio.
At the intermediate concentrations (2 to 5 g/mL),
no significant difference with the control group could be
observed in contrast to the highest concentrations (20
to 100 g/mL). In the latter, the normal osteoblast func-
tion is reflected by an intact nodule formation and a
normal alkaline phosphatase activity. However, the nod-
ules are only partly mineralized, indicating a defective
mineralization, most likely occurring secondary to a physi-
cochemical interference of Sr with hydroxyapatite forma-
tion/dissolution. These observations are also in line with
in vitro data reported by Christoffersen et al [43], evi-
dencing that synthetically prepared hydroxyapatite, in
which up to 10 mol % Ca was replaced by Sr, has a
higher solubility than the Sr-free hydroxyapatite.
Verbeckmoes, De Broe, and D’Haese: Strontium and in vitro mineralization542
Complex dose-depending effects of Sr on Ca metabo-
lism have recently been published by other investigators
[44, 45]. An explanation for the multiphasic interference
with the osteoblastic activity may be found in the calcimi-
metic properties of the element. Brown [46] has reported
that Sr has the potential to activate the extracellular Ca-
sensing receptor in both the kidney and in the parathy-
roid gland. Moreover, Somlyo and Somlyo [47] found
that Sr can be stored in the sarcoplasmic reticulum and
mitochondria of vascular smooth muscle cells, cellular
compartments known as intracellular Ca stores that play
an important role in intracellular signaling. In view of
this, together with the fact that several cellular responses
are strongly dependent on the intra- or extracellular Ca-
concentrations, one can reasonably expect that Sr may
exhibit a multiphasic effect by either stimulating or inhib-
iting the osteoblastic activity, depending on the dose.
In agreement with our previous observations in the
CRF rat [8, 9], and previous reports in literature [1, 10,
15, 48–50], a complex dose-dependent effect of Sr on
nodule formation, as well as on mineralization, could be
reproduced in our cell culture model. With regard to the
phenotypic characteristics monitored in the present in
vitro study (alkaline phosphatase, Ca incorporation) a
striking similarity with the bone histomorphometric data
of Sr-loaded CRF rats seen in a previous experimental
study [9] was found. Indeed, in these animals at serum Sr
concentrations around 1g/mL, a reduced mineral apposi-
tion and bone formation rate were noticed in the presence
of a reduced osteoblastic activity (cell biological effect),
characteristic for the presence of an adynamic bone dis-
ease. At the intermediate concentration, corresponding
with the 5 g/mL Sr group of the present study, a “nor-
mal” bone histology (i.e., a normal amount of osteoid
in combination with an intact mineral apposition and
bone formation rate) was found. Finally, in the presence
of a serum Sr level of 10g/mL, the animals presented an
impaired mineralization in the presence of an increased
amount of osteoid featuring the hallmarks of osteomala-
cia. It is worth mentioning that the range of the Sr con-
centrations applied in the present study covers the serum
concentrations found in both hemodialysis patients with
osteomalacia and adynamic bone disease (serum Sr level
0.1 to 1g/mL) [5] and postmenopausal women with osteo-
porosis (serum Sr level 10 to 20 g/mL) treated with Sr-
ranelate using doses up to 2 to 4 g/day [44, 51]. Recently,
osteomalacic lesions have also been associated with in-
creased bone Sr levels in European dialysis patients [52].
Interestingly, a comparable complex dose-dependent in-
terference with bone metabolism has previously been
shown for aluminum (Al) also in both dialysis patients
and CRF rats. In these studies the development of ady-
namic bone and osteomalacia was also seen at low and
high doses, respectively [12, 13].
Our primary cell culture data to a certain extent do
not fully agree with the in vitro findings reported by
Canalis et al [48] using calvaria organ cultures. They
found a dose-dependent stimulating effect on osteoblast
number, labeled surface, and bone formation rate. Sev-
eral important differences in experimental setup should
be taken into account when comparing our data with
the results obtained by these investigators. In contrast
to our long- term osteoblast cultures, in which consistent
multiphasic effects of Sr exposure were seen over the
whole culture period (21 days), the latter investigators
incubated their organ cultures with Sr for only 24, 48,
and 96 hours.
CONCLUSION
Using the proposed model we have been able to dem-
onstrate a multiphasic effect of Sr on the in vitro bone
formation. Moreover, these data allow us to suggest that,
at lower concentrations, the interference of Sr with the
bone formation is cell-mediated, most probably at the
level of osteoprogenitor cell differentiation. At high Sr
concentrations no effect on the osteoblast differentiation
could be observed; therefore, the disturbed mineraliza-
tion is suggested to result from a physicochemical inter-
action.
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